Table 1 Baseline characteristics of subjects

Sex (M: F ratio)

54/80 (0.67)

62/73 (0.85)

0.87^†

BMI (kg/m²)

26.76 (0.38)

27.21 (0.37)

0.41

Weight (kg)

69.50 (1.32)

69.92 (1.24)

0.58

FPG (mg/dl)

125.80 (2.22)

123.65 (1.73)

0.401

Hb A1C (%)

6.26 (0.06)

6.28 (0.07)

0.69

Insulin (uU/ml)

16.96 (0.68)

17.47 (0.67)

0.56

HOMA-IR

5.24 (0.24)

5.38 (0.23)

0.72

HOMA-β

108.44(5.48)

113.26 (5.67)

0.32

Adiponectin (ng/ml)

8.85 (0.11)

8.75 (0.12)

0.82

Leptin(ng/ml)

13.38 (0.36)

13.84 (0.34)

0.20

Creatinine (mg/dl)

0.87 (0.02)

0.86 (0.02)

0.77

AST (U/l)

25.01 (0.87)

25.34 (0.80)

0.58

ALT(U/l)

27.58 (1.56)

30.09 (1.50)

0.08

History of cerebrovascular disease

7 (5.2%)

5 (3.7%)

0.30^†

History of coronary artery disease

9 (6.7%)

8 (5.9%)

0.80^†

History of hypertension

82 (61.2%)

76 (51.2%)

0.68^†

History of dyslipidemia

104 (77.6%)

101 (74.8%)

0.84^†

Antihypertensive medications^†

Angiotensin receptor blockers

80 (70.2)

86 (76.1)

0.39

Calcium channel blockers

26 (22.8)

18 (15.9)

0.25

Beta blockers

21 (18.4)

17 (15.0)

0.61

Antidyslipedemic medications^†

Statins

59 (51.8)

55(48.7)

0.74